Tirzepatide's effects on sleep breathing problems and body weight over time in SURMOUNT-OSA

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atul Malhotra is funded by the National Institutes of Health (NIH). He reports income from Eli Lilly and Company, LivaNova, Zoll Medical, and Powell Mansfield. ResMed provided a philanthropic donation to the employer of AM (University of California San Diego). Ron Grunstein reports income from serving on the advisory board for Apnimed, the steering committee for SURMOUNT-OSA, Eli Lilly and Company, and lecture fees from Somnomed Department. He conducts sponsored studies with Eli Lilly and Company, Alkermes, Takeda, and Bod Science: Lambert Initiative. Ali Azarbarzin serves as a consultant for Respicardia, Eli Lilly and Company, Inspire, Amgen, and Apnimed. Apnimed is developing pharmacological treatments for Obstructive Sleep Apnea. AA's interests were reviewed by Brigham and Women's Hospital and Mass General Brigham in accordance with their institutional policies. AA also serves on the advisory board for Incannex. He is also co-inventor of intellectual property pertaining to wearable sleep apnea phenotyping, also via his Institution. Scott A. Sands received grant support from Apnimed, ProSomnus, DynaFlex, and Inspire Medial Systems, and has served as a consultant for Apnimed, Nox Medical, Inspire Medical Systems, Eli Lilly and Company, Respicardia, LinguaFlex, Incannix, and Achaemenid. He receives royalties for intellectual property pertaining to combination pharmacotherapy for sleep apnea via his Institution. He is also co-inventor of intellectual property pertaining to wearable sleep apnea phenotyping also via his Institution. He has received equity in Achaemenid, a company commercializing biosensor technology for monitoring oral appliance treatment efficacy. He is also co-inventor of intellectual property pertaining to wearable sleep apnea phenotyping, also via his Institution. His industry interactions are actively managed by his Institution. XD, SC, JPD and BF are employees of Eli Lilly and Company. JB contributed to the manuscript as an employee of Eli Lilly and Company.